New combo tackles tough lung cancer

NCT ID NCT05815160

Terminated Disease control Sponsor: Debiopharm International SA Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times

Summary

This early-phase study tested a new drug (Debio 0123) combined with standard chemotherapy in 34 adults whose small cell lung cancer returned after prior treatment. The main goals were to find a safe dose and check for side effects. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinica Universidad de Navarra

Madrid, 28027, Spain
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Quironsalud Malaga

Málaga, 29004, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC)

Madrid, 28050, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario de A Coruna

A Coruña, 15006, Spain
Institut Catala D'Oncologia - Badalona

Barcelona, 08908, Spain
NEXT Oncology Madrid

Madrid, 28223, Spain
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.

SMALL CELL LUNG CANCER RECURRENT